ArticleAnnals of internal medicine2018

Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.

Aoife M Egan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.